Home
HelpTest Code 2INHE Factor II Inhibitor Evaluation, Plasma
Ordering Guidance
This test is for factor II inhibitors only. If the presence or type of inhibitor is unknown, first order APROL / Prolonged Clot Time Profile, Plasma, except for patients with known hemophilia A or B. When screening studies are needed for patients with known hemophilia A or B, order 8INHE / Factor VIII Inhibitor Evaluation, Plasma; or 9 INHE / Factor IX Inhibitor Evaluation, Plasma; respectively.
Shipping Instructions
Send all vials in the same shipping container.
Necessary Information
Specimen Required
Specimen Type: Platelet-poor plasma
Patient Preparation:
1. Patient must not be receiving Coumadin (warfarin) or heparin therapy
2. Fasting preferred
Collection Container/Tube: Light-blue top (3.2% sodium citrate)
Submission Container/Tube: Plastic vials
Specimen Volume: 3 mL in 3 plastic vials, each containing 1 mL
Collection Instructions:
1. Specimen must be collected prior to factor replacement therapy.
2. For complete instructions, see Coagulation Guidelines for Specimen Handling and Processing.
3. Centrifuge, transfer all plasma into a plastic vial, and centrifuge plasma again.
4. Aliquot plasma (1-2 mL per aliquot) into 3 separate plastic vials leaving 0.25 mL in the bottom of centrifuged vial.
5. Freeze plasma immediately (no longer than 4 hours after collection) at -20° C or, ideally, -40° C or below.
Additional Information:
1. Double-centrifuged specimen is critical for accurate results as platelet contamination may cause spurious results.
2. Each coagulation assay requested should have its own vial.
Useful For
Detection and quantitation of inhibitor to factor II
This test is not useful for the detection of a lupus-like circulating anticoagulant inhibitor, a nonspecific circulating anticoagulant, or other inhibitors that are not specific for coagulation factors.
Profile Information
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| 2INHT | FII Inhib Profile Tech Interp | No | Yes |
| F_2 | Coag Factor II Assay, P | Yes | Yes |
Reflex Tests
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| 2AINH | FII Inhib Profile Prof Interp | No | No |
| F2_IS | Factor II Inhib Scrn | No | No |
| GBETH | General Factor Bethesda Units, P | No | No |
Testing Algorithm
Testing begins with coagulation factor II activity assay with dilutions to evaluate assay inhibition; if the factor II activity assay is normal or increased, a technical interpretation will be provided.
If the factor II activity assay is decreased, an inhibitor screen will be performed at an additional charge to look for specific factor II inhibition, and a professional interpretation will be provided. If specific inhibition is apparent, the titer of the inhibitor will be determined.
Special Instructions
Method Name
F_2, F2_IS, GBETH: Optical Clot-Based
2INHT: Technical Interpretation
2AINH: Medical Interpretation
Reporting Name
Factor II Inhib Profile, PSpecimen Type
Plasma Na CitSpecimen Minimum Volume
2 Plastic vials, each containing1 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Plasma Na Cit | Frozen | 14 days |
Reject Due To
| Gross hemolysis | Reject |
| Gross lipemia | Reject |
| Gross icterus | Reject |
Clinical Information
Coagulation factor inhibitors arise in patients who are congenitally deficient in a specific factor in response to factor replacement therapy or can either occur spontaneously without known cause or in response to a variety of medical conditions including the postpartum state, immunologic disorders, certain antibiotic therapies, some malignancies, and in the older population.
Inhibitors of factor VIII coagulant activity are the most commonly occurring of the specific factor inhibitors.
Reference Values
FACTOR II ACTIVITY ASSAY
Adults: 75-145%
Normal, full-term newborn infants or healthy premature infants may have decreased levels (≥25%) that may remain below adult levels for 180 days or more postnatal.*
*See Pediatric Hemostasis References in Coagulation Guidelines for Specimen Handling and Processing.
FACTOR II INHIBITOR SCREEN:
Negative
GENERAL FACTOR BETHESDA UNITS:
≤0.5 Bethesda Units
Interpretation
Normally, there is no inhibitor, ie, negative result.
If the screening assays indicate the presence of an inhibitor, it will be quantitated and reported in Bethesda (or equivalent) units.
Day(s) Performed
Monday through FridayReport Available
1 to 3 daysSpecimen Retention Time
7 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
85390
85210
85335 (if appropriate)
85335 (if appropriate)
85390 (if appropriate)
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| 2INHE | Factor II Inhib Profile, P | 96455-1 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| F_2 | Coag Factor II Assay, P | 3289-6 |
| 2INHT | FII Inhib Profile Tech Interp | 69049-5 |
Forms
If not ordering electronically, complete, print, and send a Coagulation Test Request (T753) with the specimen.